UT MD Anderson
@UTMDAnderson
Followers
142K
Following
40K
Media
9K
Statuses
45K
Official account of The University of Texas MD Anderson Cancer Center. Our mission is to #EndCancer through patient care, research, education & prevention.
Houston, TX
Joined February 2008
Drs. @CheenuKappadath and @ArmeenMahvash have spent much of their careers researching how to help patients with hepatocellular carcinoma live longer — and they recently unlocked a new treatment. More about this practice-changing work: https://t.co/wJRlpISWO1
#EndCancer
mdanderson.org
Results of research from UT MD Anderson recently led to Food and Drug Administration (FDA) approval for the use of SIR-Spheres as a first-line treatment against unresectable and unablatable hepatoc...
0
2
3
The new Colorectal Center at our Texas Medical Center Campus brings together specialized expertise, supportive services and a thoughtfully designed environment in one location. Learn more: https://t.co/kdpp4Q6K04
#EndCancer
0
2
11
A targeted therapy plus chemotherapy combination treatment was found to be safe and effective for patients with leptomeningeal metastases from breast cancer in a Phase II trial, led by UT MD Anderson researchers: https://t.co/zAhLnoh1x0
#EndCancer
0
7
26
From robotic lung biopsies to image-guided spine surgery, virtual models are helping to make cancer surgery safer. Learn how: https://t.co/hZwdIsc8DF
#EndCancer
0
2
11
Pappas Restaurants is again supporting our mission to #EndCancer. Through March 31, guests can donate at participating restaurants and honor someone they love with a personalized sticker. Donate online: https://t.co/2gkoynpy13
0
4
15
New data from UT MD Anderson researchers found that blocking both CD47 and CD24 proteins heightened the immunotherapy response in GBM models. What's next for this approach: https://t.co/RgVp06QOkj
@BettyKimLab #EndCancer
mdanderson.org
Dual targeting approach improves immunotherapy response in glioblastoma
0
6
40
Data from a recent study challenges the long-held belief that high testosterone fuels early-stage prostate cancer growth. Why baseline testosterone may serve as a useful clinical marker to stratify risk of disease progression: https://t.co/Pi6XM5fwX8
@JustinRGregg #EndCancer
mdanderson.org
2
4
9
Happy to share our work in Leukemia, showing that donor selection (specifically DPB1 mismatching) can be harnessed to measurably reduce relapse in high risk AML/MDS patients, without effect on GVHD. https://t.co/Myf7hKly6X
@UTMDAnderson #bmtsm #leusm
nature.com
Leukemia - Reduced relapse in high risk acute myeloid leukemia and myelodysplastic neoplasms with permissive HLA-DPB1 mismatches and post-transplant cyclophosphamide
1
7
33
Registration is open for ALIGN 2026. This two-day conference will be filled with insightful dialogue, groundbreaking innovations and meaningful collaboration centered on aligning care with what matters most to patients: https://t.co/Ql1yAjjWqJ
#EndCancer
0
4
13
Congratulations to our @ppisters on receiving the Charles M. Balch, M.D., Distinguished Service Award at #SSO26. This prestigious award highlights his outstanding commitment to and leadership within the field of surgical oncology. Read more: https://t.co/uSqgA5OP1H
#EndCancer
3
8
35
Treatment for locally advanced rectal cancer has used chemoradiation followed by surgery and more chemotherapy. But this has been "turned on its head by recent data," says @JoshSmithMDPhD. This research will be discussed at #SSO26: https://t.co/VSslihtj6i
#EndCancer
mdanderson.org
Thanks to clinical trials, treatment for locally advanced rectal cancer has shifted to frontload radiation and chemotherapy before surgery, allowing some patients to forgo surgery all together. Josh...
0
4
13
Our researchers recently discovered a less common subtype of metastatic colorectal cancer that responds well to immunotherapy. Dr. Scott Kopetz shares more about the finding and the latest in colorectal cancer research: https://t.co/sh4FUtjusT
@skopetz #EndCancer
mdanderson.org
Is immunotherapy a treatment option for colorectal cancer patients? Gastrointestinal medical oncologist Scott Kopetz, M.D., Ph.D., shares which patients are benefiting from immune checkpoint inhibi...
0
5
19
From expanding patient navigation to making lifesaving research breakthroughs, UT MD Anderson redefined what is possible in our mission to end cancer in Fiscal Year 2025. Read our latest Annual Report to see what’s only possible here: https://t.co/BCF5VL6ZsI
#EndCancer
0
3
15
Support UT MD Anderson in Round 1 of #STATMadness. Three of our research studies are in the competition, reflecting the innovation and collaboration that drive our mission to end cancer. Help advance our work by casting your vote. https://t.co/LCm5EkZNrL
#EndCancer
statnews.com
2026 bracket Welcome to STAT Madness, a bracket-style contest to find the best innovation in science and medicine. Explore groundbreaking innovations from
0
3
14
Four exceptional scientists have been appointed to the James P. Allison Institute at UT MD Anderson. They bring expertise in immune therapy resistance, cancer vaccines, bioengineering, tumor evolution and drug development: https://t.co/k3mialSxWo
#EndCancer @BettyKimLab
0
8
48
Playing for a cause 🧡 The Houston Dash are proud to continue wearing @MDAndersonNews as our front of kit sponsor. Together we raise vital awareness and funding for cancer patient care, research, education and prevention.
0
15
64
The @US_FDA approved encorafenib plus cetuximab and fluorouracil-based chemotherapy for adults with metastatic colorectal cancer who have a BRAF V600E mutation. The decision is based on results from the BREAKWATER clinical trial, co-led by our Dr. Scott Kopetz. #EndCancer
FDA grants traditional approval to a treatment for metastatic colorectal cancer with a BRAF V600E mutation. https://t.co/d2NERaNqS8
0
5
33
Take a look inside MD Anderson's new Colorectal Center, which opened this week. The environment is designed to minimize stress and maximize comfort, centering on the needs of patients and their caregivers. #ColorectalCancer #EndCancer
1
8
42